HROW

Harrow (HROW)

About Harrow (HROW)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Details

Daily high
$41.12
Daily low
$39.84
Price at open
$39.97
52 Week High
$54.85
52 Week Low
$28.54
Market cap
1.5B
Dividend yield
0.00%
Volume
322,835
Avg. volume
495,671
P/E ratio
-97.70

Harrow News

Details

Daily high
$41.12
Daily low
$39.84
Price at open
$39.97
52 Week High
$54.85
52 Week Low
$28.54
Market cap
1.5B
Dividend yield
0.00%
Volume
322,835
Avg. volume
495,671
P/E ratio
-97.70